In alignment with the national framework for the advancement of proton therapy, facilitated by the National Cancer Center, HKSH Medical Group (HKSH) and Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen (Shenzhen Cancer Hospital) have signed a Memorandum of Understanding (MoU).
This collaboration aims to enhance collaborative efforts in clinical applications of proton therapy, specialist training, and cancer management research, reinforcing HKSH's collaboration with the National Cancer Center to address the heightened demand for proton therapy nationwide and to advance collective anti-cancer initiatives.
The MoU is established as a foundation for both parties to engage in short-term and long-term collaborations, share best practices in healthcare, training management, and the cultivation of medical talent, and jointly enhance and promote cancer care services to meet international standards. Furthermore, they will extend mutual assistance and share expertise in advanced cancer treatment protocols, clinical trials for pharmaceuticals, and high-end medical services.
A primary objective of the "Healthy China 2030" plan is to improve survival rates for cancer patients. High-precision proton therapy, which minimises adverse side effects, has emerged as a pivotal approach for achieving the goal. In June 2025, HKSH, in collaboration with the National Cancer Center and the Cancer Hospital Chinese Academy of Medical Sciences, co-hosted the Proton Therapy Joint Training Programme in Beijing. HKSH inaugurated a ten-month HKSH Proton Training Programme in August, and successfully organised the annual conference of Asia-Oceania Particle Therapy Cooperative Group in November, convening global leaders in proton therapy to advance the field of precision cancer treatment.
